vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Waterstone Financial, Inc. (WSBF). Click either name above to swap in a different company.
Waterstone Financial, Inc. is the larger business by last-quarter revenue ($37.2M vs $18.6M, roughly 2.0× SCYNEXIS INC). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 16.7%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 7.1%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Waterstone Financial, Inc. is a U.S. bank holding company headquartered in Wisconsin. It offers retail and commercial banking services, residential mortgages, and wealth management solutions, primarily serving consumers and small to medium-sized businesses across the U.S. Midwest region.
SCYX vs WSBF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $37.2M |
| Net Profit | $12.3M | — |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 27.0% |
| Net Margin | 65.7% | — |
| Revenue YoY | 1808.5% | 16.7% |
| Net Profit YoY | 376.5% | — |
| EPS (diluted) | $0.25 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $37.2M | ||
| Q3 25 | $334.0K | $37.0M | ||
| Q2 25 | $1.4M | $38.0M | ||
| Q1 25 | $257.0K | $29.7M | ||
| Q4 24 | $977.0K | $31.8M | ||
| Q3 24 | $660.0K | $34.1M | ||
| Q2 24 | $736.0K | $37.2M | ||
| Q1 24 | $1.4M | $32.4M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | $7.9M | ||
| Q2 25 | $-6.9M | $7.7M | ||
| Q1 25 | $-5.4M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | $4.7M | ||
| Q2 24 | $-14.5M | $5.7M | ||
| Q1 24 | $411.0K | $3.0M |
| Q4 25 | 56.3% | 27.0% | ||
| Q3 25 | -2516.5% | 26.6% | ||
| Q2 25 | -701.0% | 25.4% | ||
| Q1 25 | -3350.2% | 13.1% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | -1563.6% | 17.3% | ||
| Q2 24 | -1255.0% | 19.2% | ||
| Q1 24 | -692.5% | 14.7% |
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | 21.4% | ||
| Q2 25 | -504.8% | 20.3% | ||
| Q1 25 | -2097.7% | 10.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | 13.9% | ||
| Q2 24 | -1964.4% | 15.4% | ||
| Q1 24 | 29.9% | 9.4% |
| Q4 25 | $0.25 | $0.43 | ||
| Q3 25 | $-0.17 | $0.45 | ||
| Q2 25 | $-0.14 | $0.43 | ||
| Q1 25 | $-0.11 | $0.17 | ||
| Q4 24 | — | $0.28 | ||
| Q3 24 | $-0.06 | $0.26 | ||
| Q2 24 | $-0.30 | $0.31 | ||
| Q1 24 | $0.01 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | — |
| Total DebtLower is stronger | — | $412.3M |
| Stockholders' EquityBook value | $49.4M | $349.4M |
| Total Assets | $59.0M | $2.3B |
| Debt / EquityLower = less leverage | — | 1.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | — | ||
| Q3 25 | $37.9M | — | ||
| Q2 25 | $44.8M | — | ||
| Q1 25 | $40.6M | — | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | — | ||
| Q2 24 | $73.0M | — | ||
| Q1 24 | $80.2M | — |
| Q4 25 | — | $412.3M | ||
| Q3 25 | — | $469.1M | ||
| Q2 25 | — | $465.7M | ||
| Q1 25 | — | $395.9M | ||
| Q4 24 | — | $446.5M | ||
| Q3 24 | — | $560.1M | ||
| Q2 24 | — | $660.8M | ||
| Q1 24 | — | $634.2M |
| Q4 25 | $49.4M | $349.4M | ||
| Q3 25 | $36.4M | $345.5M | ||
| Q2 25 | $44.5M | $341.5M | ||
| Q1 25 | $50.5M | $341.4M | ||
| Q4 24 | $55.1M | $339.1M | ||
| Q3 24 | $58.5M | $342.0M | ||
| Q2 24 | $60.4M | $334.9M | ||
| Q1 24 | $74.1M | $338.0M |
| Q4 25 | $59.0M | $2.3B | ||
| Q3 25 | $51.1M | $2.3B | ||
| Q2 25 | $60.7M | $2.3B | ||
| Q1 25 | $67.9M | $2.2B | ||
| Q4 24 | $90.6M | $2.2B | ||
| Q3 24 | $99.0M | $2.2B | ||
| Q2 24 | $107.8M | $2.3B | ||
| Q1 24 | $118.3M | $2.2B |
| Q4 25 | — | 1.18× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | — | 1.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $24.2M |
| Free Cash FlowOCF − Capex | — | $23.0M |
| FCF MarginFCF / Revenue | — | 61.9% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $43.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $24.2M | ||
| Q3 25 | $-8.7M | $32.7M | ||
| Q2 25 | $-7.5M | $-38.4M | ||
| Q1 25 | $-7.5M | $26.7M | ||
| Q4 24 | $-24.0M | $48.1M | ||
| Q3 24 | $765.0K | $74.1M | ||
| Q2 24 | $-10.9M | $-39.5M | ||
| Q1 24 | $-4.0M | $-9.9M |
| Q4 25 | — | $23.0M | ||
| Q3 25 | — | $32.4M | ||
| Q2 25 | — | $-38.5M | ||
| Q1 25 | — | $26.5M | ||
| Q4 24 | — | $47.0M | ||
| Q3 24 | — | $73.9M | ||
| Q2 24 | — | $-39.7M | ||
| Q1 24 | — | $-10.3M |
| Q4 25 | — | 61.9% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | -101.2% | ||
| Q1 25 | — | 89.2% | ||
| Q4 24 | — | 147.5% | ||
| Q3 24 | — | 216.9% | ||
| Q2 24 | — | -106.7% | ||
| Q1 24 | — | -31.9% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.2% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | 4.13× | ||
| Q2 25 | — | -4.98× | ||
| Q1 25 | — | 8.81× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 15.67× | ||
| Q2 24 | — | -6.92× | ||
| Q1 24 | -9.75× | -3.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
WSBF
Segment breakdown not available.
